Napp Pharmaceuticals Limited

Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0GW
Telephone: +44 (0)1223 424 444
Fax: +44 (0)1223 424 441
WWW: http://www.napp.co.uk
Medical Information Fax: +44 (0)1223 424 912
Patient Information Leaflet last updated on the eMC: 23/09/2009
PIL BuTrans transdermal patch (5ug/h, 10ug/h and 20ug/h)

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 03/07/2009 and displayed until 23/09/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 18/03/2009 and displayed until 03/07/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 22/05/2008 and displayed until 18/03/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 24/07/2007 and displayed until 22/05/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to side-effects
  • Change due to user-testing of patient information
Updated on 01/09/2006 and displayed until 24/07/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 28/10/2005 and displayed until 01/09/2006
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   buprenorphine


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk